

Statement on Immunizations in the Kidney Community

General Practice

The American Society of Nephrology (ASN) encourages all health professionals who interact with kidney patients to follow immunization recommendations from the Centers for Disease Control and Prevention (CDC) in order to reduce the risks from vaccine-preventable illness in people with kidney diseases.

ASN supports the use of the "Standards for Adult Immunization Practice" (SAIP) as guidance for promoting immunization practices:¹

- ASSESS⁴ a patient's immunization status at serial clinical encounters on an ongoing basis. Stay informed of the latest CDC recommendations as well as implement protocols and policies to support routine review of the individual patient's eligibility for vaccines and distribute reminder communications to the patient for needed vaccines.
- 2. RECOMMEND⁵ vaccines to all eligible patients with messaging tailored to the individual patient, meeting language needs and addressing questions posed by the patient.
- 3. ADMINISTER⁶ vaccines on site or REFER⁶ to a provider who can immunize.
- 4. DOCUMENT⁷ vaccines received by your patients through follow-up communication and participation in your state's immunization registry.

ASN also recommends that health professionals and the public remain up to date with CDC vaccine recommendations⁸, which prevent or mitigate the risks from the illnesses listed in Table 1.

Champion vaccinations for people with kidney diseases

ASN recommends that kidney health professionals be proactive in promoting the importance and receipt of vaccinations for all people with kidney diseases.

Prioritize vaccinations for people with kidney diseases not on kidney replacement therapy

ASN recommends that patients with kidney diseases receive all recommended vaccinations prior to initiating dialysis or receiving a transplant. These vaccines should remain up to date thereafter. This approach offers optimal efficacy and protection against preventable illness.

Establish an immunization plan for people with kidney diseases on dialysis or living with a kidney transplant

ASN recommends that dialysis-dependent patients and those living with a kidney transplant receive all CDC recommended vaccinations. The provision of vaccinations that provide protection to people with kidney diseases, who are dialysis-dependent or living with a kidney transplant, commands special attention and an awareness of CDC vaccination guidance for immunocompromised conditions.⁹

Table 1: Illnesses with a CDC Vaccine
Recommendation for Adults ²
COVID-19 ³
Haemophilus influenzae type b
Hepatitis A
Hepatitis B
Herpes Zoster (Shingles)
Influenza
Measles, mumps, rubella
Meningococcal A, C, W, Y
Meningococcal B
Pneumococcal
Tetanus, diphtheria, pertussis
Varicella (Chickenpox)



Children

ASN recommends that children with kidney diseases receive all vaccines for which they are eligible to protect themselves from serious illness. ASN suggests that interested kidney health professionals reference the immunization schedules for children and adolescents available from CDC.¹⁰

Vigilance

New vaccines are assessed by a long-standing, rigorous, and transparent process administered by the US Food and Drug Administration (FDA) and CDC, where clinical trial data is reviewed and evaluated before authorization. FDA monitors vaccines closely for adverse events that were not previously reported in clinical trials. ASN recommends that kidney health professionals be familiar with CDC's Vaccine Adverse Event Reporting System (VAERS) and participate in this reporting as appropriate.¹¹

Before FDA approves or provides emergency use authorization (EUA), a vaccine must go through phases of clinical trials to ensure its safety and efficacy. Clinical trial study populations, however, may not include people living with kidney diseases, people who are dialysis-dependent, or people who have a kidney transplant. Studies that include these populations may occur after recommendations made for patients without kidney diseases are issued.

CDC immunization guidance is reviewed and updated annually by the Advisory Committee on Immunization Practices (ACIP)¹² to account for the emergence of new information. ASN urges kidney health professionals to be aware of vaccine recommendations and best practice guidance from ACIP.

Summary

ASN recommends that kidney health professionals stay current with immunization practice guidelines and be cognizant of the unique needs of patients across the spectrum of kidney diseases who are at increased risk of infection from vaccine-preventable illnesses and the severe complications that may result.

Given the frequency of clinical encounters, kidney health professionals are uniquely poised to optimize vaccine administration and reduce infection risk by:

- Facilitating the tracking and documentation of every patient's vaccine status.
- Assessing a patient's vaccination status at least annually based on recommended immunization schedules and CDC guidance.
- Offering vaccination-related information championed through the voice of the interdisciplinary team.
- Administering vaccines during a clinical encounter or referring to a vaccine provider, if vaccine/vaccines cannot be administered at the nephrology office, dialysis facility, or transplant center.
- Maintaining effective immunization data tracking systems and follow-up communications with the individual patient.

About the American Society of Nephrology

Established in 1966, the American Society of Nephrology's (ASN) mission is to create a world without kidney diseases. ASN elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative change in kidney medicine. Under the guidance of the Excellence in Patient Care Advisory Committee, ASN performs quality improvement initiatives and activities, which produce virtual learning modules, webinars, podcasts, and materials for dialysis facility staff and kidney patients. Learn more about the ASN by visiting http://www.asn-online.org. This document was created by ASN's Adult Immunization Project Task Force under the direction of Rebecca Schmidt, DO, FASN—Chair of the ASN Adult Immunization Project Task Force.



References

[1] CDC Standards for Adult Immunization Practice (SAIP)

https://www.cdc.gov/vaccines/hcp/adults/for-practice/standards/index.html

[2] CDC Adult Immunization Schedule

https://www.cdc.gov/vaccines/schedules/hcp/imz/adult.html

[3] CDC Stay Up to Date with Your Vaccines

https://www.cdc.gov/coronavirus/2019-ncov/vaccines/stay-up-to-date.html

[4] Standards: Vaccine Assessment

https://www.cdc.gov/vaccines/hcp/adults/for-practice/standards/assessment.html

[5] Standards: Vaccine Recommendation

https://www.cdc.gov/vaccines/hcp/adults/for-practice/standards/recommend.html

[6] Standards: Vaccine Administration and Referral

https://www.cdc.gov/vaccines/hcp/adults/for-practice/standards/referral.html

[7] Standards: Documentation

https://www.cdc.gov/vaccines/hcp/adults/for-practice/standards/documentation.html

[8] CDC What Vaccines Are Recommend for You

https://www.cdc.gov/vaccines/adults/rec-vac/index.html

[9] CDC Extra Precautions – People with Medical Conditions

https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html#immunocompromised

[10] CDC Child and Adolescent Immunization Schedule https://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-child-combined-schedule.pdf

[11] Vaccine Adverse Event Reporting System (VAERS)

https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/vaers.html

[12] Vaccine Recommendations and Guidance of the ACIP

https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/general-recs-errata.html?ACSTrackingID=USCDC 11 7-DM81312



Disease	Replacement Therapy <or> Adult Kidney Patients Who are Dialysis Dependent or are thri</or>				Rep < <o< th=""><th>Adult Patients who are moderately / severely immunocompromised or are thriving with a Kidney Transplant</th><th>Child and Adole age) Kidney Pat</th><th>-</th><th>th to 18</th><th>years of</th></o<>	Adult Patients who are moderately / severely immunocompromised or are thriving with a Kidney Transplant	Child and Adole age) Kidney Pat	-	th to 18	years of
Coronavirus Disease 2019 (COVID-19)	Pfizer- BioNTech	Age Group: 18 years and older Up to date: immediately after receiving the most recent booster as recommended	Primary series 1st dose	Primary series 2nd dose (3-8 weeks after 1st dose)	Updated (bivalent) Booster* 3rd dose (at least 2 months after primary series or last booster) *Updated booster can be Pfizer-BioNTech or Moderna	Age Group: 18 years and older Up to date: immediately after receiving the most recent booster as recommended 1st dose – primary series 2nd dose – primary series (3 weeks after 1st dose) 3rd dose – primary series (at least 4 weeks after 2nd dose) 4th dose – updated booster* (at least 2 months after 3rd dose or last booster)	Age Group: 6 months to 4 years Up to date: 2 weeks after 3rd dose (booster not recommended) Age Group: 5 to 11 years Up to date immediately after 3rd dose	Primary series 1st dose Primary series 1st dose	Primary series 2nd dose (3-8 weeks after 1st dose) Primary series 2nd dose (3-8 weeks after 1st dose)	Primary series 3rd dose (at least 8 weeks after 2nd dose) Updated Booster 3rd dose (at least 2 months after 2nd dose or last booster, children aged 5 years can only get Pfizer-BioNTech booster, children aged 6-11 years can get a Pfizer-BioNTech or Moderna booster.)



Disease	Vaccine	Replacement Therapy < <or> Adult Kidney Patients who are Dialysis Dependent</or>			Adult Patients who are moderately / severely immunocompromised or are thriving with a Kidney Transplant	Child and Adole age) Kidney Pati	ears of			
							Age Group: 12 to 17 years Up to date: immediately after receiving the most recent booster as recommended	Primary series 1st dose	Primary series 2nd dose (3-8 weeks after 1st dose)	Updated Booster* 3rd dose (at least 2 months after 2nd dose or last booster)
	Moderna	Age Group: 18 years and older Up to date: immediately after receiving	Primary series 1st dose	Primary series 2nd dose (4-8 weeks after 1st dose)	Updated (bivalent) Booster* 3rd dose (at least 2 months	Age Group: 18 years and older Up to date: immediately after receiving the most recent booster as recommended • 1st dose – primary	Age Group: 6 months to 4 years Up to date: two weeks after 2nd dose (booster not recommended)	Primary series 1st dose	Primary set 2nd dose (4-8 weeks dose)	
		the most recent booster as recommended			after primary series or last booster) *Updated booster can be	series 2nd dose – primary series (4 weeks after 1st dose) 3rd dose – primary series (at least 4 weeks after 2nd dose) 4th dose – updated booster* (at least 2	Age Group: 5 years Up to date: immediately after receiving the most recent booster as recommended	Primary series 1st dose	Primary series 2nd dose (4-8 weeks after 1st dose)	Updated Booster 3rd dose (at lest 2 months after 2nd, can only get Pfizer- BioNTech booster)



Disease	Vaccine	Replacement Therapy < <or> Adult Kidney Patients who are Dialysis Dependent</or>			Adult Patients who are moderately / severely immunocompromised or are thriving with a Kidney Transplant	Child and Adolescent (birth to 18 years) Kidney Patients			years of	
					Pfizer- BioNTech or Moderna	months after 3rd dose or last booster)	Age Group: 6 to 17 years Up to date: immediately after receiving the most recent booster as recommended	Primary series 1st dose	Primary series 2 2nd dose (4-8 weeks after 1st dose)	Updated Booster* 3rd dose (at least 2 months after 2nd dose or last booster)
	Novavax	Age Group: 18 years and older Up to date: immediately after receiving the most recent booster as recommended	Primary series 1st dose	Primary series 2nd dose (3-8 weeks after 1st dose)	Updated (bivalent) Booster* 3rd dose (at least 2 months after primary series or last booster) *Updated booster can	Age Group: 12 years and older Up to date: immediately after receiving the most recent booster as recommended 1st dose – primary series 2nd dose – primary series (3 weeks after 1st dose) 3rd dose – updated booster* (at least 2 months after 2nd dose)	Not recommend 12 years of age. Age Group: 12 to 17 years Up to date: immediately after receiving the most recent booster as recommended Novavax is not at this time.	Primary series 1st dose	Primary series 2nd dose (3-8 weeks after 1st dose)	Updated Booster* 3rd dose (at least 2 months after 2nd dose)
					be Pfizer- BioNTech		this time.			



Disease	Vaccine	Adult Kidney Pati Replacement The < <or>> Adult Kidney Pati</or>	rapy			Adult Patients who are moderately / severely immunocompromised or are thriving with a Kidney Transplant	Child and Adolescent (birth to 18 years of age) Kidney Patients
					or Moderna		
	Johnson & Johnson's Janssen	and older for whom	other author	2r 2 do bo *U ca Bi M	roved COVID-19 v	accines are not accessi	(not approved for children at this time) sen COVID-19 Vaccine to individuals 18 years of age ole or clinically appropriate, and to individuals 18 ey would otherwise not receive a COVID-19



Disease	Vaccine	Adult Kidney Patients Prior to Initiating Renal Replacement Therapy < <or> Adult Kidney Patients who are Dialysis Dependent</or>	Adult Patients who are moderately / severely immunocompromised or are thriving with a Kidney Transplant	Child and Adolescent (birth to 18 years of age) Kidney Patients		
Dengue	Dengvaxia	(not applicable)	(not applicable)			
Haemophilus influenzae type b	Hib	Recommended for adults with additional risk factor or a	nother indication	3- or 4-dose series depending on vaccine (at age 2m, 4m, 6m, 12-15 months)		
Hepatitis A	НерА	Recommended for adults with additional risk factor or a	2-dose series at age 12-13 months, minimum interval 6 months			
Hepatitis B	НерВ	2, 3, or 4 doses depending on vaccine or cond	3-dose series at age 0, 1-2, 6-18 months			
Human papillomavirus	HPV	2 or 3 doses through age 26 depending on age at initial vaccination or condition	3 doses through age 26	2- or 3-dose series depending on age at initial vaccination		
Influenza	IIV4 or RIV4	One dose annually		Annually, 1 to 2 doses for ages 6 months through 8 years Annually, one dose for all persons aged 9 or order		
	LAIV4	(precaution)	(contraindicated)	(precaution)		
Measles, mumps, and rubella	MMR	1 or 2 doses depending on indication	(contraindicated)	2-dose series at age 12-15 months, age 4-6 years		
Meningococcal	MenACWY			2-dose series at age 11-12 years, 16 years		
	MenB	Dosing and boosters depending on risk factor or anot	Dosing and boosters depending on risk factor or another indication			
Pneumococcal	PCV15	1 dose PCV15 followed by PPSV23 after minimum of 8 wee		PCV13 = 4-dose series at age 2, 4, 6, 12-15		
	PCV20	OR PPSV23 followed by either a PCV15 or PCV20 (a	PSV23 followed by either a PCV15 or PCV20 (after 1 year)			



Disease	Vaccine	Adult Kidney Patients Prior to Initiating Renal Replacement Therapy < <or>> Adult Kidney Patients who are Dialysis Dependent</or>	Adult Patients who are moderately / severely immunocompromised or are thriving with a Kidney Transplant	Child and Adolescent (birth to 18 years of age) Kidney Patients		
	PPSV23 (PCV13	PPSV23 at age 65 or older – with least 5 years between o	/13 before age 65 followed by 2 doses of PPSV23 before age 65 and 1 dose of PSV23 at age 65 or older – with least 5 years between doses of PPSV23			
	historic)	9.	Visit CDC's Pneumococcal vaccine timing page at https://www.cdc.gov/vaccines/vpd/pneumo/downloads/pneumo-vaccine-timing.pdf			
PolioVirus	IPV	(not applicable)	4-dose series at ages 2m,4m, 6-18 months, 4-6 years			
Rotavirus	Rotarix RotaTeq	(not applicable)		2-dose series at age 2 and 4 months 3 dose series at age 2, 4 and 6 months		
Shingles	RZV	2 doses at age ≥ 50	2 doses by age ≥ 19	(not applicable)		
Tetanus, diphtheria, and pertussis	Tdap or Dp	1 dose Tdap, then Td; or Tdap booster every 10) years	5-dose series at age 2m, 4m, 6m, 15-18 months, 4-6 years		
Varicella	VAR	2 doses	(contraindicated)	2-dose series at age 12-15 months, age 4-6 years		



Document Control

Document Information					
Document Owner	Shane Perry, Project Specialist				
Issue Date	September 2022				
File Name	ASN Immunization Statement – Final				
Uploaded to Web	October 2022				

	Document History						
Version	Issue Date	Changes					
1	June 2022	Document created					
2	July 2022	COVID-19 vaccine recommendations updated					
3	September 2022	COVID-19 vaccine recommendations updated					
4	October 2022	COVID-19 vaccine recommendations updated					

Document Approvals							
Role	Name	Date					
ASN's Adult Immunization Project Advisory Committee	Rebecca Schmidt, DO, Chair	7/2022					
ASN Council	Susie Stark, ASN Vice President,	8/2022					
	Excellence in Patient Care						